HRP20170001T1 - Nove podgrupe pacijenata za trombolizu - Google Patents

Nove podgrupe pacijenata za trombolizu Download PDF

Info

Publication number
HRP20170001T1
HRP20170001T1 HRP20170001TT HRP20170001T HRP20170001T1 HR P20170001 T1 HRP20170001 T1 HR P20170001T1 HR P20170001T T HRP20170001T T HR P20170001TT HR P20170001 T HRP20170001 T HR P20170001T HR P20170001 T1 HRP20170001 T1 HR P20170001T1
Authority
HR
Croatia
Prior art keywords
desmoteplase
patient
use according
stroke
cerebral
Prior art date
Application number
HRP20170001TT
Other languages
English (en)
Croatian (hr)
Inventor
Mariola Söhngen
Alice Ebel
Yasir Alaa Shafeek Al-Rawi
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170001(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07020401A external-priority patent/EP2050462A1/en
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20170001T1 publication Critical patent/HRP20170001T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
HRP20170001TT 2007-10-18 2008-10-20 Nove podgrupe pacijenata za trombolizu HRP20170001T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07020401A EP2050462A1 (en) 2007-10-18 2007-10-18 Improved treatment of stroke patients
EP07022867 2007-11-26
EP08017954 2008-10-15
PCT/EP2008/008871 WO2009049914A2 (en) 2007-10-18 2008-10-20 Novel patient subgroups for thrombolysis
EP08838897.0A EP2211898B1 (en) 2007-10-18 2008-10-20 Novel patient subgroups for thrombolysis

Publications (1)

Publication Number Publication Date
HRP20170001T1 true HRP20170001T1 (hr) 2017-02-24

Family

ID=40567844

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170001TT HRP20170001T1 (hr) 2007-10-18 2008-10-20 Nove podgrupe pacijenata za trombolizu

Country Status (28)

Country Link
US (2) US20100272704A1 (enExample)
EP (1) EP2211898B1 (enExample)
JP (2) JP5509085B2 (enExample)
KR (1) KR20100089077A (enExample)
CN (1) CN101903039B (enExample)
AR (1) AR068914A1 (enExample)
AU (1) AU2008314048B2 (enExample)
BR (1) BRPI0817785A2 (enExample)
CA (1) CA2702378A1 (enExample)
CL (1) CL2009000752A1 (enExample)
CY (1) CY1118417T1 (enExample)
DK (1) DK2211898T3 (enExample)
EA (1) EA020776B1 (enExample)
ES (1) ES2611155T3 (enExample)
HR (1) HRP20170001T1 (enExample)
HU (1) HUE032867T2 (enExample)
IL (1) IL205175A0 (enExample)
LT (1) LT2211898T (enExample)
MX (1) MX2010004157A (enExample)
MY (1) MY159200A (enExample)
NZ (1) NZ584640A (enExample)
PL (1) PL2211898T3 (enExample)
PT (1) PT2211898T (enExample)
RS (1) RS55590B1 (enExample)
SI (1) SI2211898T1 (enExample)
TW (1) TWI482628B (enExample)
WO (1) WO2009049914A2 (enExample)
ZA (1) ZA201002548B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5244806A (en) * 1985-08-26 1993-09-14 Eli Lilly And Company DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
US5094953A (en) * 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
FI100403B (fi) * 1988-07-20 1997-11-28 Schering Ag Menetelmä glykosyloitujen tai glykosyloimattomien vampyyrilepakon sylj en plasminogeeniaktivaattoreiden valmistamiseksi
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US6008019A (en) * 1989-02-13 1999-12-28 Schering Aktiengesellschaft Plasminogen activator from saliva of the vampire bat
US5891664A (en) * 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
DK0580685T3 (da) * 1991-04-16 1996-03-04 Boehringer Mannheim Gmbh Farmaceutisk emballageenhed indeholdende plasminogenaktivatorer til flerfoldig bolusindgift
US5595736A (en) * 1991-04-22 1997-01-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders
RU2183214C2 (ru) * 1992-12-04 2002-06-10 Шеринг Аг Природный и рекомбинантный ингибиторы тромбина, их получение и применение
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5731186A (en) * 1996-02-05 1998-03-24 Schering Aktiengesellschaft Method for the production of rDSPA α1
US6354999B1 (en) * 2000-01-14 2002-03-12 Florence Medical Ltd. System and method for detecting, localizing, and characterizing occlusions and aneurysms in a vessel
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
KR20060015721A (ko) * 2003-05-05 2006-02-20 파이온 도이치란트 게엠베하 신경보호제로서의 글루타메이트 수용체 길항제
US20050085478A1 (en) * 2003-08-22 2005-04-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
WO2007025219A2 (en) * 2005-08-25 2007-03-01 Biogen Idec Ma Inc. Nogo receptor polypeptides and polypeptide fragments and uses thereof

Also Published As

Publication number Publication date
CL2009000752A1 (es) 2009-12-04
HK1151233A1 (en) 2012-01-27
RS55590B1 (sr) 2017-06-30
HUE032867T2 (en) 2017-11-28
JP2014065739A (ja) 2014-04-17
US20140314736A1 (en) 2014-10-23
AU2008314048B2 (en) 2013-07-25
CA2702378A1 (en) 2009-04-23
MX2010004157A (es) 2010-04-30
JP5509085B2 (ja) 2014-06-04
EA201070485A1 (ru) 2010-10-29
AU2008314048A1 (en) 2009-04-23
EA020776B1 (ru) 2015-01-30
ES2611155T3 (es) 2017-05-05
JP2011500617A (ja) 2011-01-06
TWI482628B (zh) 2015-05-01
KR20100089077A (ko) 2010-08-11
PL2211898T3 (pl) 2017-03-31
SI2211898T1 (sl) 2017-02-28
ZA201002548B (en) 2011-06-29
CN101903039A (zh) 2010-12-01
MY159200A (en) 2016-12-30
LT2211898T (lt) 2017-01-25
DK2211898T3 (en) 2017-01-30
WO2009049914A2 (en) 2009-04-23
AR068914A1 (es) 2009-12-16
EP2211898B1 (en) 2016-12-07
BRPI0817785A2 (pt) 2015-03-24
NZ584640A (en) 2012-10-26
WO2009049914A3 (en) 2009-08-06
CY1118417T1 (el) 2017-06-28
IL205175A0 (en) 2010-11-30
PT2211898T (pt) 2017-01-31
US20100272704A1 (en) 2010-10-28
TW200927164A (en) 2009-07-01
EP2211898A2 (en) 2010-08-04
CN101903039B (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
Chimowitz Endovascular treatment for acute ischemic stroke—still unproven
Shevchenko et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis
Raza et al. Extracorporeal shockwave therapy for peripheral arterial disease: a review of the potential mechanisms of action
Leslie-Mazwi et al. Intra-arterial air thrombogenesis after cerebral air embolism complicating lower extremity sclerotherapy
Ciccocioppo et al. Perspectives of the international society for cell & gene therapy gastrointestinal scientific committee on the intravenous use of mesenchymal stromal cells in inflammatory bowel disease (PeMeGi)
Tajiri et al. Cerebral aneurysm as an exacerbating factor in stroke pathology and a therapeutic target for neuroprotection
HRP20170001T1 (hr) Nove podgrupe pacijenata za trombolizu
Klevanets et al. Systemic thrombolytic therapy and catheter-directed fragmentation with local thrombolytic therapy in patients with pulmonary embolism
Aldandashi et al. Combination treatment with dipyridamole, aspirin, and tPA in an embolic model of stroke in rats
WO2016164534A1 (en) Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
JP2017508768A5 (enExample)
Tao et al. Renoprotective effects of remote ischemic preconditioning on acute kidney injury induced by repeated tourniquet application in patients undergoing extremity surgery
Jiyanboyevich et al. The Comparison between management versus percutaneous coronary intervention (PCI) patients with coronary artery disease (CAD)
Wang et al. Successful treatment with recombinant blood factor VIIa in severe postpartum hemorrhage-induced disseminated intravascular coagulation
MX2023005663A (es) Tratamientos respiratorios.
Panova et al. Synthesis of the matrix metalloproteinases and its inhibitors by peripheral blood phagocytes of women with hypertansion disorders
Wang et al. Acute normovolemic hemodilution combined with controlled hypotension does not increase incidence of postoperative cognitive dysfunction in elderly spinal surgery patients
Cohen et al. Major Stroke After Spontaneous Carotid Artery Dissection with Associated Thrombus in a Patient with COVID-19: Carotid Angioplasty, Clot Aspiration Under Balloon Guiding Catheter-Assisted Flow Arrest, Stenting, and Mechanical Thrombectomy; Is COVID-19 a Risk Factor for Carotid Dissection and Stroke?
Hirsh Advances and contemporary issues in prophylaxis for deep vein thrombosis
Sosa et al. LETTER TO THE EDITOR–not commissioned
Sran et al. The role of interferon in premature atherosclerosis in systemic lupus erythematosus patients
Dariusz et al. Blood Pressure Management in Acute Ischemic Stroke
Palaiodimou et al. Acute Blood Pressure Management
NO20073635L (no) Kombinasjonsbehandling for multippel sklerose
Isacco et al. Chronic migraine-cephalgia related to trigeminal artery: a case report of innovative regenerative approach